China's First ever CRISPR Cas9 system Patent!

Hi Folks!! Follow our blog on Instagram


China’s patent and trademark office has upheld a key patent within the portfolio of CRISPR/Cas9 intellectual property belonging to Nobel Laureate Emmanuelle Charpentier, The Regents of the University of California, and University of Vienna (known collectively as CVC), and licensed for commercial use through ERS Genomics.
Dublin-based ERS Genomics said the China National Intellectual Property Administration (CNIPA) has upheld Patent No. CN201380038920.6, “Methods and Compositions for RNA-guided Target DNA Modification and for RNA-guided Transcription Regulation”.ToolGen claims that it was the world’s first filer of patents covering gene editing in eukaryotic cells using the CRISPR-Cas9 system.
“The decision by the CNIPA fully upholding the patent further demonstrates its validity and value as part of the patent collection for use of the CRISPR/Cas9 technology,” ERS Genomics stated in announcing the Chinese decision recently.The CVC patents have faced numerous challenges from competing companies and researchers.              
The European Patent Office (EPO) has affirmed two CVC patents known as EP2800 811 in 2020 and EP3401400 in 2022, though oral arguments for the appeal of these affirmations are scheduled for October.In the U.S., the use of CRISPR-Cas9 in eukaryotic cells has been enmeshed in a nearly decade-long bitter battle royale over who invented the genome editing technology.


NOTE:

1.ERS Genomics is the global leader in providing access to foundational patents covering CRISPR/Cas9 intellectual property and licencing.

2.Dublin is the capital and largest city of Ireland.

3.CVC is the CRISPR Cas 9 Portfolio, a medium via which various patents under CRISPR are provided                                                                            





Comments

Popular posts from this blog

XPOSAT - STUDY ABOUT BLACKHOLE(A GIST)

CELL CRYOPRESERVATION